secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2022-07-27T23:59:59+00:00
Accession:  0000950170-22-013150
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics appoints Sekar Kathiresan, M.D. to Board of Directors
------------------------------------------------------------------------

- Dr. Kathiresan appointed as class III director effective July 25, 2022, filling a newly created vacancy expanding board to eight members.
- He is co-founder and CEO of Verve Therapeutics (VVTA) and serves on its board; previously director at MGH Center for Genomic Medicine and Broad Institute.
- He will receive an initial option grant for 71,881 shares vesting over 36 months, plus standard non-employee director compensation.
- Also appointed to the Nominating and Corporate Governance Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017022013150/0000950170-22-013150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017022013150/rlay-20220725.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-013150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer